Lehtonen A, Gordin A, Salo H
Int J Clin Pharmacol Ther Toxicol. 1987 Jun;25(6):301-5.
The effect of once daily sustained release verapamil (200-400 mg/day) and low dose hydrochlorothiazide (25 mg/day) on blood pressure and metabolic parameters was compared in a cross-over study. The treatment periods lasted 6 months. The antihypertensive efficacy of verapamil was comparable to that of low dose hydrochlorothiazide. Plasma total cholesterol, LDL cholesterol, HDL cholesterol or triglycerides did not change significantly from the values at the end of the drug free run-in period either on verapamil or on hydrochlorothiazide. Statistically, serum insulin decreased significantly with verapamil (13.4 +/- 4.3 U/ml, m +/- SD) when compared with both the wash-out (16.2 +/- 5.7 U/ml) and hydrochlorothiazide (17.1 +/- 6.5 ml) periods. There were no significant differences in fasting blood glucose between the treatment periods. Serum uric acid concentration increased significantly (from 266 +/- 64 mumol/l) after the wash-out period (to 307 +/- 92 mumol/l) after hydrochlorothiazide, but did not change on verapamil (270 +/- 75 mumol/l). Serum potassium decreased significantly from 3.96 +/- 0.39 mmol/l after the wash-out period to 3.67 +/- 0.37 mmol/l on hydrochlorothiazide, but did not change on verapamil (3.94 +/- 0.28 mmol/l).
在一项交叉研究中，比较了每日一次缓释维拉帕米（200 - 400毫克/天）和低剂量氢氯噻嗪（25毫克/天）对血压和代谢参数的影响。治疗期持续6个月。维拉帕米的降压疗效与低剂量氢氯噻嗪相当。无论是服用维拉帕米还是氢氯噻嗪，血浆总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇或甘油三酯与无药导入期结束时的值相比均无显著变化。统计学上，与洗脱期（16.2±5.7 U/ml）和氢氯噻嗪期（17.1±6.5 ml）相比，服用维拉帕米时血清胰岛素显著降低（13.4±4.3 U/ml，均数±标准差）。各治疗期之间空腹血糖无显著差异。氢氯噻嗪治疗后，血清尿酸浓度在洗脱期后显著升高（从266±64 μmol/l升至307±92 μmol/l），但服用维拉帕米时无变化（270±75 μmol/l）。血清钾在洗脱期后从3.96±0.39 mmol/l显著降至氢氯噻嗪治疗后的3.67±0.37 mmol/l，但服用维拉帕米时无变化（3.94±0.28 mmol/l）。
